» Articles » PMID: 26429337

Qualitative Analysis of Patient-centered Decision Attributes Associated with Initiating Hepatitis C Treatment

Overview
Publisher Biomed Central
Specialty Gastroenterology
Date 2015 Oct 3
PMID 26429337
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In this era of a constantly changing landscape of antiviral treatment options for chronic viral hepatitis C (CHC), shared clinical decision-making addresses the need to engage patients in complex treatment decisions. However, little is known about the decision attributes that CHC patients consider when making treatment decisions. We identify key patient-centered decision attributes, and explore relationships among these attributes, to help inform the development of a future CHC shared decision-making aid.

Methods: Semi-structured qualitative interviews with CHC patients at four Veterans Health Administration (VHA) hospitals, in three comparison groups: contemplating CHC treatment at the time of data collection (Group 1), recently declined CHC treatment (Group 2), or recently started CHC treatment (Group 3). Participant descriptions of decision attributes were analyzed for the entire sample as well as by patient group and by gender.

Results: Twenty-nine Veteran patients participated (21 males, eight females): 12 were contemplating treatment, nine had recently declined treatment, and eight had recently started treatment. Patients on average described eight (range 5-13) decision attributes. The attributes most frequently reported overall were: physical side effects (83%); treatment efficacy (79%), new treatment drugs in development (55%); psychological side effects (55%); and condition of the liver (52%), with some variation based on group and gender. Personal life circumstance attributes (such as availability of family support and the burden of financial responsibilities) influencing treatment decisions were also noted by all participants. Multiple decision attributes were interrelated in highly complex ways.

Conclusions: Participants considered numerous attributes in their CHC treatment decisions. A better understanding of these attributes that influence patient decision-making is crucial in order to inform patient-centered clinical approaches to care (such as shared decision-making augmented with relevant decision-making aids) that respond to patients' needs, preferences, and circumstances.

Citing Articles

An evolutionary concept analysis: stigma among women living with hepatitis C.

Masterman C, Mendlowitz A, Capraru C, Campbell K, Eastabrook G, Yudin M BMC Public Health. 2024; 24(1):2660.

PMID: 39342214 PMC: 11439273. DOI: 10.1186/s12889-024-20131-6.


Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections.

Welzel T, Yang M, Sajeev G, Chen Y, Pinsky B, Bao Y Adv Ther. 2019; 36(9):2475-2486.

PMID: 31240629 PMC: 6822851. DOI: 10.1007/s12325-019-01012-6.


Implementing prescription drug monitoring and other clinical decision support for opioid risk mitigation in a military health care setting: a qualitative feasibility study.

Finley E, Schneegans S, Tami C, Pugh M, McGeary D, Penney L J Am Med Inform Assoc. 2017; 25(5):515-522.

PMID: 29025024 PMC: 7646964. DOI: 10.1093/jamia/ocx075.


What's Important to the Patient? Informational Needs of Patients Making Decisions About Hepatitis C Treatment.

Evon D, Golin C, Stoica T, Jones R, Willis S, Galanko J Patient. 2016; 10(3):335-344.

PMID: 27882509 PMC: 5597439. DOI: 10.1007/s40271-016-0207-7.

References
1.
Abraham N, Naik A, Street Jr R . Shared decision making in GI clinic to improve patient adherence. Clin Gastroenterol Hepatol. 2012; 10(8):825-7. DOI: 10.1016/j.cgh.2012.06.001. View

2.
Rosedale M, Strauss S . How persons with chronic hepatitis C in residential substance abuse treatment programs think about depression and interferon therapy. J Am Psychiatr Nurses Assoc. 2011; 16(6):350-6. DOI: 10.1177/1078390310392784. View

3.
Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon S . Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368(20):1878-87. DOI: 10.1056/NEJMoa1214853. View

4.
Naik A . On the road to patient centeredness. JAMA Intern Med. 2013; 173(3):218-9. DOI: 10.1001/jamainternmed.2013.1229. View

5.
Spiegel B, Younossi Z, Hays R, Revicki D, Robbins S, Kanwal F . Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005; 41(4):790-800. DOI: 10.1002/hep.20659. View